Print
Email
SaveHealthline's Premium Tools
Symptom Search
Discover possible causes based on the symptoms you enter. It's fast, convenient and easy to use.
Discover possible causes based on the symptoms you enter. It's fast, convenient and easy to use.
Healthline Part D Plan Selector
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
|
... she had no desire to ever run another one. That all changed in May, when her mother-in-law, Lee, was diagnosed with Acute Myeloid Leukemia (AML). "The same week the packet came in the mail for the marathon was the same week Lee was diagnosed," she ...
|
|
... a first-in-class pan Bcl-2 inhibitor. Obatoclax is currently in Phase 2 clinical trials for the treatment of elderly acute myeloid leukemia and the treatment of small cell lung cancer. " This key patent is core to our overall IP strategy and ...
|
|
The difficulties faced in management and treatment of leukemias are magnified when discussing acute myeloid leukemia .
|
|
... in several model systems, including neuronal and hematopoietic cells. We demonstrated that CREB is overexpressed in acute myeloid and leukemia cells compared to normal hematopoietic stem cells. CREB knockdown inhibits leukemic cell proliferation in ...
|
|
... study is designed as a protocol amendment expanding the ongoing Phase 2 trial of sapacitabine in elderly patients with acute myeloid leukemia (AML) to include a cohort of patients with MDS. MDS are a group of hematologic cancers in which the bone ...
|
|
Main Category: Lymphoma / Leukemia Also Included In: Blood / Hematology ; Clinical Trials / Drug Trials ; Seniors / Aging Article Date: 15 Sep 2008 - 2:00 PDT Cyclacel Pharmaceuticals, Inc.
|
|
Abstract OBJECTIVE: MEIS1, a HOX cofactor, collaborates with multiple HOX and NUP98-HOX fusion proteins to accelerate the onset of acute myeloid leukemia through largely unknown molecular mechanisms.
|
|
... benefit other families in Sarnia/Lambton County, as that is... Emilie's Legacy In 2004, Emilie was diagnosed with myeloid dysplastic syndrome, MDS, a rare cancer. However, complicating the matter was the fact that Emilie had an abnormal chromosome ...
|
|
... team involved in the clinical trial of LOR-2040 and high dose cytarabine for treatment of refractory and relapsed acute myeloid leukemia under the overall direction of Dr. Guido Marcucci as Principal Investigator and Dr. Kenneth Chan, Co-Director of ...
|
|
Celator Pharmaceuticals today announced that the U.S. Food & Drug Administration has granted orphan drug designation to CPX-351 Liposome Injection for the treatment of Acute Myeloid Leukemia .
|
|
Abstract The molecular heterogeneity of acute leukemias and other tumors constitutes a major obstacle towards understanding disease pathogenesis and developing new targeted-therapies. Aberrant gene regulation ...
|
 |
 |
Home | About | Health Experts | Careers | Site Map | Feedback | Help | Health Tools | Tell a Friend
Advertise | Terms of Use | Privacy Policy
Advertise | Terms of Use | Privacy Policy
Copyright © 2005 - 2008 Healthline Networks, Inc. All rights reserved.